US biopharma Amgen has agreed to buy privately held clinical-stage biotech Teneobio in a deal worth up to $2.5 billion. The acquisition will expand Amgen’s antibody...
14.02.2019
- US biopharma AbbVie has agreed a deal with Teneobio, a California-based biotech, to develop and commercialize an immunotherapeutic that targets B-cell maturation antigen (BCMA) for...
